SCHEDULE: Alyeska Investment Discloses 2.58% Stake in IN8BIO

Alyeska Investment Group, L.P. and its affiliates reported a 2.58% beneficial ownership stake in IN8BIO, INC., primarily through warrants.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 89,021 shares of IN8BIO, INC. Common Stock.
• This ownership represents 2.58% of IN8BIO's outstanding common stock.
• The reported shares are held as warrants to purchase Class A common stock.
• The percentage calculation is based on 3,444,234 outstanding shares of Common Stock, as reported by IN8BIO in its Form 8-K filed on June 4, 2025.
• The reporting persons, including an investment adviser and an individual, hold shared voting and dispositive power over all 89,021 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral, factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape, but rather details a specific investment position.

Stakeholder Impact

• Provides transparency to shareholders and the market regarding significant ownership stakes by institutional investors.
• Informs potential investors about the composition of the company's shareholder base.

Key Dates

Keywords

IN8BIO, Alyeska Investment Group, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Warrants, Biotechnology, Investment Management